OS in the (A) ITT population and in the (B) subset of patients with an HRRm. In the ITT population, the OS rates at 18 months were 29.9% (95% CI, 19.6 to 40.8) in the durvalumab plus olaparib group and 38.7% (95% CI, 27.5 to 49.7) in the durvalumab plus placebo group. HR, hazard ratio; HRRm, mutations in homologous recombination repair genes; HRRwt, wild-type homologous recombination repair genes; ITT, intent-to-treat; OS, overall survival; PFS, progression-free survival.